Home » Stocks » INMB

Inmune Bio Inc. (INMB)

Stock Price: $9.64 USD -0.42 (-4.17%)
Updated May 13, 2021 2:52 PM EDT - Market open
Market Cap 152.61M
Revenue (ttm) 10,916
Net Income (ttm) -14.58M
Shares Out 14.93M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $9.64
Previous Close $10.06
Change ($) -0.42
Change (%) -4.17%
Day's Open 10.20
Day's Range 9.32 - 10.28
Day's Volume 162,910
52-Week Range 4.50 - 29.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Company to host conference call today, May 5, at 4:30pm ET Company to host conference call today, May 5, at 4:30pm ET

1 week ago - GlobeNewsWire

Management to host conference call at 4:30 pm ET on that day Management to host conference call at 4:30 pm ET on that day

2 weeks ago - GlobeNewsWire

LA JOLLA, Calif, April 26, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patie...

2 weeks ago - GlobeNewsWire

Innate Killer Digital Summit 2021, which is being held March 23-25

1 month ago - GlobeNewsWire

Company to host conference call today, March 4, at 4:30pm ET Company to host conference call today, March 4, at 4:30pm ET

2 months ago - GlobeNewsWire

The wild ride for the biotech stock started with its announcement of results from a phase 1b study.

3 months ago - The Motley Fool

Interim data show CSF biomarkers of neurodegeneration and synaptic dysfunction as well as neuroimaging biomarkers improved after three months of therapy with XPro1595

3 months ago - GlobeNewsWire

Webinar to review expanded biomarker data from the company's Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patients with Alzheimer's disease

4 months ago - GlobeNewsWire

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities ...

5 months ago - Insider Monkey

In this article we present the list of Top 10 Stocks Billionaire George Soros Just Bought. Click to skip ahead and see the  Top 5 Stocks Billionaire George Soros Just Bought .

Other stocks mentioned: DIS, MCHP, MXIM, NGHC, NXPI, PLTR, PPG ...
5 months ago - Insider Monkey

LA JOLLA, Calif, Nov. 09, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innat...

6 months ago - GlobeNewsWire

INmune Bio, Inc. (INMB) CEO RJ Tesi on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Management to host conference call at 4:30 pm ET on that day

6 months ago - GlobeNewsWire

LA JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s inna...

7 months ago - GlobeNewsWire

LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patien...

7 months ago - GlobeNewsWire

100 patient blinded, randomized, biomarker-directed Phase 2 study will use neuroimaging technology to study the complex biology of treatment resistant disease

7 months ago - GlobeNewsWire

LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s i...

8 months ago - GlobeNewsWire

LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s in...

9 months ago - GlobeNewsWire

INmune Bio Inc. (INMB) CEO RJ Tesi on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

The company will host an earnings call: Today, August 5 at 4:30 PM ET The company will host an earnings call: Today, August 5 at 4:30 PM ET

9 months ago - GlobeNewsWire

LA JOLLA, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a pa...

9 months ago - GlobeNewsWire

LA JOLLA, Calif, July 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s in...

9 months ago - GlobeNewsWire

LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, July 20th by INmune Bio, Inc. (NASDAQ: INMB) was incorrectly reported with below sentence:

9 months ago - GlobeNewsWire

LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a pat...

9 months ago - GlobeNewsWire

LA JOLLA, Calif, July 16, 2020 (GLOBE NEWSWIRE) --   INmune Bio, Inc.  (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a...

9 months ago - GlobeNewsWire

INmune Bio: Stronger Support From Alzheimer's Drug XPro1595

9 months ago - Seeking Alpha

LA JOLLA, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness...

9 months ago - GlobeNewsWire

Inmune Bio (INMB) stock is taking off on Tuesday after announcing positive Alzheimer's news for its leading drug candidate XPro1595.

9 months ago - InvestorPlace

Inmune Bio stock skyrocketed to a record high Tuesday after the biotech company unveiled promising results for its Alzheimer's treatment. The drug targets inflammation in the brain.

9 months ago - Investors Business Daily

Micro-cap biotech INmune Bio Inc (NASDAQ: INMB) is advancing strongly Tuesday following a positive clinical readout from the company.

9 months ago - Benzinga

XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory

9 months ago - GlobeNewsWire

Study will be the first-in man trial for INKmune – a novel therapy to prime the patient’s own NK cells to attack their cancer

11 months ago - GlobeNewsWire

Review highlights the history, progress and potential of cells of the innate immune system that can be harnessed for treatment of cancer

11 months ago - GlobeNewsWire

INmune Bio Inc. (INMB) CEO RJ Tesi on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

The company will host an earnings call: Today, May 14 at 4:30 PM ET The company will host an earnings call: Today, May 14 at 4:30 PM ET

11 months ago - GlobeNewsWire

LA JOLLA, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune syst...

1 year ago - GlobeNewsWire

Conference call at 4:15 PM ET with management to discuss the science and strategy of clinical trial to determine if  the Company’s DN-TNF platform could be used to treat catastrophic complications of...

1 year ago - GlobeNewsWire

INmune Bio Inc. (INMB) CEO R.J.

1 year ago - Seeking Alpha

Grant will fund proof-of-concept studies for XPro1595 therapy

1 year ago - GlobeNewsWire

Dr. Malú Tansey's peer-reviewed data from INmune Bio's lead compound XPro1595 published in Alzheimer's Research & Therapy Dr. Malú Tansey's peer-reviewed data from INmune Bio's lead compound XPro1595 pu...

1 year ago - GlobeNewsWire

Phase II program to focus on women with trastuzumab resistant HER2+ breast cancer

1 year ago - GlobeNewsWire

About INMB

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancer... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 2019
Stock Exchange
NASDAQ
Ticker Symbol
INMB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Inmune Bio stock is "Buy." The 12-month stock price forecast is 29.50, which is an increase of 206.02% from the latest price.

Price Target
$29.50
(206.02% upside)
Analyst Consensus: Buy